Max Brosa

1.7k total citations
91 papers, 1.2k citations indexed

About

Max Brosa is a scholar working on Epidemiology, Economics and Econometrics and Surgery. According to data from OpenAlex, Max Brosa has authored 91 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Epidemiology, 18 papers in Economics and Econometrics and 17 papers in Surgery. Recurrent topics in Max Brosa's work include Health Systems, Economic Evaluations, Quality of Life (14 papers), Pharmaceutical Economics and Policy (7 papers) and Asthma and respiratory diseases (7 papers). Max Brosa is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (14 papers), Pharmaceutical Economics and Policy (7 papers) and Asthma and respiratory diseases (7 papers). Max Brosa collaborates with scholars based in Spain, France and United Kingdom. Max Brosa's co-authors include Carlos Crespo, Marı́a Buti, Rafael Esteban, Miguel Á. Casado, Marc Miravitlles, Xavier Badı́a, Julia Álvarez Hernández, A. López-Alba, Bernat Soria and M. François and has published in prestigious journals such as SHILAP Revista de lepidopterología, Social Science & Medicine and Journal of Hepatology.

In The Last Decade

Max Brosa

84 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max Brosa Spain 18 310 303 247 197 170 91 1.2k
Norio Hanafusa Japan 26 228 0.7× 150 0.5× 278 1.1× 383 1.9× 120 0.7× 138 2.0k
Talar Markossian United States 21 277 0.9× 77 0.3× 209 0.8× 187 0.9× 58 0.3× 63 1.4k
Lisa Rosenblatt United States 24 214 0.7× 111 0.4× 89 0.4× 82 0.4× 57 0.3× 111 1.6k
Janak de Zoysa New Zealand 19 131 0.4× 151 0.5× 563 2.3× 248 1.3× 25 0.1× 61 1.4k
Gabriel Mircescu Romania 20 123 0.4× 242 0.8× 177 0.7× 123 0.6× 58 0.3× 105 1.6k
Holly K. Van Houten United States 25 299 1.0× 205 0.7× 138 0.6× 611 3.1× 83 0.5× 75 2.4k
A. De Vecchi Italy 16 176 0.6× 321 1.1× 126 0.5× 272 1.4× 91 0.5× 41 1.4k
Elizabeth H. Jones United Kingdom 12 106 0.3× 214 0.7× 202 0.8× 158 0.8× 50 0.3× 39 1.2k
Susan Murin United States 25 436 1.4× 265 0.9× 663 2.7× 507 2.6× 28 0.2× 51 2.8k
Blanca Coll‐Vinent Spain 24 219 0.7× 69 0.2× 711 2.9× 124 0.6× 36 0.2× 91 2.1k

Countries citing papers authored by Max Brosa

Since Specialization
Citations

This map shows the geographic impact of Max Brosa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Brosa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Brosa more than expected).

Fields of papers citing papers by Max Brosa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Brosa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Brosa. The network helps show where Max Brosa may publish in the future.

Co-authorship network of co-authors of Max Brosa

This figure shows the co-authorship network connecting the top 25 collaborators of Max Brosa. A scholar is included among the top collaborators of Max Brosa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Brosa. Max Brosa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Naranjo, Antonio, et al.. (2022). Cost-Effectiveness Analysis of Fracture Liaison Services Compared with Standard of Care in the Secondary Prevention of Fragility Fractures in Spain. ClinicoEconomics and Outcomes Research. Volume 14. 249–264. 13 indexed citations
2.
Brosa, Max, et al.. (2019). PRO80 COMPARISON OF EARLY ACCESS PROGRAMMES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES. Value in Health. 22. S855–S856. 1 indexed citations
3.
Dégano, Irene R., Isaac Subirana, Danilo Fusco, et al.. (2017). Percutaneous coronary intervention reduces mortality in myocardial infarction patients with comorbidities: Implications for elderly patients with diabetes or kidney disease. International Journal of Cardiology. 249. 83–89. 15 indexed citations
4.
Morell, Ferrán, et al.. (2016). Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel. BMC Pulmonary Medicine. 16(1). 7–7. 17 indexed citations
5.
Figueras, M., et al.. (2016). Cost-Effectiveness Analysis of Sacubitril/Valsartan in Chronic Heart Failure with Reduced Ejection Fraction in Spain. Value in Health. 19(7). A650–A650. 1 indexed citations
6.
7.
8.
León‐Sanz, M., et al.. (2015). PREDyCES study: The cost of hospital malnutrition in Spain. Nutrition. 31(9). 1096–1102. 46 indexed citations
9.
10.
Rodríguez, José María Fernández, et al.. (2013). Cost-Effectiveness Analysis of Dapaglifozin Versus Other T2DM Treatments in the Spanish Context. Value in Health. 16(7). A439–A439. 1 indexed citations
11.
Crespo, Carlos, et al.. (2013). Direct Cost of Diabetes Mellitus and Its Complications in Spain. Seccaid Study: Spain Estimated Cost Ciberdem-Cabimer in Diabetes. Value in Health. 16(7). A436–A436. 12 indexed citations
12.
Crespo, Carlos, Josè Antonio Pérez-Simón, José Manuel Rodrı́guez, Jordi Sierra, & Max Brosa. (2012). Development of a Population-Based Cost-Effectiveness Model of Chronic Graft-Versus-Host Disease in Spain. Clinical Therapeutics. 34(8). 1774–1787. 12 indexed citations
13.
14.
Benito, Pere, et al.. (2011). Economic evaluation of tramadol/paracetamol in the management of pain in patients with osteoarthritis in Spain. Reumatología Clínica (English Edition). 7(4). 241–247. 3 indexed citations
15.
Villanueva, Vicente, et al.. (2011). PMH70 Economic Impact of Focal Epilepsy in Spain: Results of the Espera Study. Value in Health. 14(7). A299–A299. 1 indexed citations
16.
Indinnimeo, M, et al.. (2010). Sacral Neuromodulation for the Treatment of Fecal Incontinence: Analysis of Cost-Effectiveness. Diseases of the Colon & Rectum. 53(12). 1661–1669. 21 indexed citations
17.
Moreu, José, Ángel Cequier, Max Brosa, et al.. (2009). Evaluación económica e impacto presupuestario del stent recubierto Endeavor® en España. Hispana. 5 indexed citations
18.
Buti, Marı́a, Ramón San Miguel, Max Brosa, et al.. (2005). Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. Journal of Hepatology. 42(5). 639–645. 82 indexed citations
19.
Badı́a, Xavier, et al.. (1999). [Evidence-based medicine, health costs and treatment of intra-abdominal infection].. PubMed. 17 Suppl 2. 86–94. 4 indexed citations
20.
Badı́a, Xavier, et al.. (1989). Aproximación a un análisis coste-utilidad de la terapéutica transfusión/eritropoyetina en los pacientes afectos de anemia nefrológica en hemodiálisis: Resultados del estudio en curso. 11(1). 15–20. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Norio Hanafusa Breakdown of academic impact, for papers by Talar Markossian Breakdown of academic impact, for papers by Lisa Rosenblatt Breakdown of academic impact, for papers by Janak de Zoysa Breakdown of academic impact, for papers by Gabriel Mircescu Breakdown of academic impact, for papers by Holly K. Van Houten Breakdown of academic impact, for papers by A. De Vecchi Breakdown of academic impact, for papers by Elizabeth H. Jones Breakdown of academic impact, for papers by Susan Murin Breakdown of academic impact, for papers by Blanca Coll‐Vinent
Rankless by CCL
2026